US Stock MarketDetailed Quotes
KYTX Kyverna Therapeutics
- 5.530
- +0.150+2.79%
Close Oct 16 16:00 ET
- 5.620
- +0.090+1.63%
Post 20:02 ET
238.60MMarket Cap-2603P/E (TTM)
5.830High5.380Low325.41KVolume5.460Open5.380Pre Close1.83MTurnover1.45%Turnover RatioLossP/E (Static)43.15MShares35.06052wk High0.72P/B123.72MFloat Cap4.40052wk Low--Dividend TTM22.37MShs Float35.060Historical High--Div YieldTTM8.36%Amplitude4.400Historical Low5.638Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Kyverna Therapeutics Stock Forum
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet